AI assistant
Royalty Pharma plc — Director's Dealing 2025
Dec 9, 2025
30286_dirs_2025-12-09_af2d2b2b-aada-4eb9-9a32-83c951dbeda1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-12-05
Reporting Person: Urist Marshall (EVP, Research & Investments)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-05 | Class A Ordinary Shares | S | 23334 | $39.1528 | Disposed | 160000 | Indirect |
| 2025-12-05 | Class A Ordinary Shares | S | 18242 | $39.1527 | Disposed | 7398 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Ordinary Shares | 19020 | Indirect |
Footnotes
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.